ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Breviscapine alleviates NASH by inhibiting TGF-β-activated kinase 1-dependent signaling

Lan, Tian; Jiang, Shuo; Zhang, Jing; Weng, Qiqing; Yu, Yang; Li, Haonan; Tian, Song; Ding, Xin; Hu, Sha; Yang, Yiqi; Wang, Weixuan; Wang, Lexun; Luo, Duosheng; Xiao, Xue; Piao, Shenghua; Zhu, Qing; Rong, Xianglu; Guo, Jiao广东药学院; 武汉大学
Hepatology2022-7DOI: 10.1002/hep.32221
31被引9阅读
引用收藏
分享

摘要

Background and Aims NAFLD is a key component of metabolic syndrome, ranging from nonalcoholic fatty liver to NASH, and is now becoming the leading cause of cirrhosis and HCC worldwide. However, due to the complex and unclear pathophysiological mechanism, there are no specific approved agents for treating NASH. Breviscapine, a natural flavonoid prescription drug isolated from the traditional Chinese herb Erigeron breviscapus, exhibits a wide range of pharmacological properties, including effects on metabolism. However, the anti-NASH efficacy and mechanisms of breviscapine have not yet been characterized. Approach and Results We evaluated the effects of breviscapine on the development of hepatic steatosis, inflammation, and fibrosis in vivo and in vitro under metabolic stress. Breviscapine treatment significantly reduced lipid accumulation, inflammatory cell infiltration, liver injury, and fibrosis in mice fed a high-fat diet, a high-fat/high-cholesterol diet, or a methionine- and choline-deficient diet. In addition, breviscapine attenuated lipid accumulation, inflammation, and lipotoxicity in hepatocytes undergoing metabolic stress. RNA-sequencing and multiomics analyses further indicated that the key mechanism linking the anti-NASH effects of breviscapine was inhibition of TGF-beta-activated kinase 1 (TAK1) phosphorylation and the subsequent mitogen-activated protein kinase signaling cascade. Treatment with the TAK1 inhibitor 5Z-7-oxozeaenol abrogated breviscapine-mediated hepatoprotection under metabolic stress. Molecular docking illustrated that breviscapine directly bound to TAK1. Conclusion Breviscapine prevents metabolic stress-induced NASH progression through direct inhibition of TAK1 signaling. Breviscapine might be a therapeutic candidate for the treatment of NASH.

学科与关键词

关键词
FATTY LIVER-DISEASESCUTELLARININFLAMMATIONPATHOGENESISSTRESSRESISTANCENAFLDMICE
相关
加载中…
  • Kinsenoside alleviates inflammation and fibrosis in experimental NASH mice by suppressing the NF-ΚB/NLRP3 signaling pathway
    Deng, Yan-fang; Xu, Qian-qian; Chen, Tian-qi; Ming, Jia-xiong; Wang, Ya-fen; Mao, Li-na; Zhou, Jia-jun; Sun, Wei-guang*; Zhou, Qun*; Ren, Hong*; Zhang, Yong-hui*PHYTOMEDICINE, 2022, 104: 154241.被引 13
  • Neferine ameliorates nonalcoholic steatohepatitis through regulating AMPK pathway
    Wang, Ming-Yue; Zhang, Shao-Shi; An, Meng - Fei; Xia, Yue-fei; Fan, Mao-Si; Sun, Ze-Rui; Zhang, Li-Juan; Zhao, Yun-Li*; Sheng, Jun*; Wang, Xuan-Jun*PHYTOMEDICINE, 2023, 114: 154798.
  • Fufang Zhenzhu Tiaozhi Capsule Prevents Intestinal Inflammation and Barrier Disruption in Mice With Non-Alcoholic Steatohepatitis
    Lan, Tian; Xu, Tonghao; Fu, Yanfang; Jiang, Shuo; Liang, Xiaolin; Yu, Ze; Pan, Linyu; Rong, Xianglu; Guo, Jiao*Frontiers in Endocrinology, 2022, 13: 864703.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Hepatology
发表日期
2022-07
卷期
第 76 卷, 第 1 期
页码
155-171
DOI
10.1002/hep.32221
语言
ENGLISH
期刊等级
1区
成果收录
SCIE
资助标注
Special Topics of General Projects of Guangzhou Science and Technology Plan of China [201904010075]; Major Basic and Applied Basic Research Projects in Guangdong Province of China [2019B030302005]; National Natural Science Foundation of China [81830113, 81870420, 82070590]; National Key R&D Plan of China "Research on Modernization of Traditional Chinese Medicine" program [2018YFC1704200]

作者

  • L

    Lan, Tian (第一作者)

    guangdong pharmaceut univ

  • J

    Jiang, Shuo

    guangdong pharmaceut univ

查看全部 18 位作者收起作者
  • Z

    Zhang, Jing

    guangdong pharmaceut univ

  • W

    Weng, Qiqing

    guangdong pharmaceut univ

  • Y

    Yu, Yang

    guangdong pharmaceut univ

  • L

    Li, Haonan

    guangdong pharmaceut univ

  • T

    Tian, Song

  • D

    Ding, Xin

    guangdong pharmaceut univ

  • H

    Hu, Sha

  • Y

    Yang, Yiqi

    guangdong pharmaceut univ

  • W

    Wang, Weixuan

    guangdong pharmaceut univ

  • W

    Wang, Lexun

    guangdong pharmaceut univ

  • L

    Luo, Duosheng

    guangdong pharmaceut univ

  • X

    Xiao, Xue

    guangdong pharmaceut univ

  • P

    Piao, Shenghua

    guangdong pharmaceut univ

  • Z

    Zhu, Qing

    guangdong pharmaceut univ

  • R

    Rong, Xianglu

    guangdong pharmaceut univ

  • G

    Guo, Jiao

    guangdong pharmaceut univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417